Endo News Roundup: Promising Diabetes Therapies


Three new studies highlight promising diabetes drug treatments to help patients who struggle with severe hyperglycemia.

New drugs show promise in treating type 2 diabetes mellitus (T2DM) patients with severe hyperglycemia, and may also lower cardiovascular disease (CVD) risks and reduce glucose variability. Here are the highlights from three new studies: a combination of saxagliptin and metformin is effective in treating severe hyperglycemia in patients with new-onset T2DM. T2DM patients treated with dipeptidyl peptidase-4 (DPP-4) inhibitors may have lower risks for CVD as compared to those for non-DPP-4 inhibitor users, except for those taking metformin. Insulin-dependent T2DM patients show reduced glucose variability when treated with a glucagon-like peptide 1 (GLP-1) agonist.

Related Videos
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Erin Michos, MD | Credit: Johns Hopkins University
Natalie McCormick, PhD | Credit: American College of Rheumatology
© 2024 MJH Life Sciences

All rights reserved.